-
Eli Lilly-Innovent Biologics Score Expanded Use Approval of Tyvyt n Lung Cancer Patients In China
Thursday, June 3, 2021 - 8:18am | 218Read More...The National Medical Products Administration (NMPA) of China has approved Innovent Biologics Inc (OTC: IVBXF) and Eli Lilly And Co's (NYSE: LLY) Tyvyt (sintilimab injection) in non-small cell lung cancer (NSCLC). The approval is for expanded use of Tyvyt in combination...
-
Amgen's First KRAS-Targeted Therapy, Lumakras Scores FDA Approval For Lung Cancer
Friday, May 28, 2021 - 2:29pm | 290Read More...The FDA has given accelerated approval to Amgen Inc's (NASDAQ: AMGN) Lumakras (sotorasib) for non-small cell lung cancer (NSCLC) patients harboring kras mutation. The approval covers the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC...
-
AstraZeneca's Tagrisso Wins European Approval In Early Lung Cancer
Friday, May 28, 2021 - 8:27am | 202Read More...AstraZeneca Plc’s (NASDAQ: AZN) top-selling Tagrisso drug has been approved for use in the European Union to treat patients with a type of early-stage lung cancer. The European Commission has approved the lung cancer drug as an add-on (adjuvant) treatment for adults diagnosed...
-
JNJ's Rybrevant Scores FDA Approval In Lung Cancer Patients With EGFR Exon 20 Mutation
Friday, May 21, 2021 - 3:56pm | 214Read More...The FDA has approved Janssen Pharmaceutical Companies' a unit of Johnson & Johnson (NYSE: JNJ) Rybrevant (amivantamab-vmjw) for a subset of non-small cell lung cancer (NSCLC). The approval covers adult patients with non-small cell lung cancer whose tumors have specific...
-
Advaxis' ADXS-503 Shows Durable Benefit Beyond One Year in Lung Cancer Patients Progressing on Merck's Keytruda
Thursday, May 20, 2021 - 10:17am | 238Read More...Advaxis Inc (NASDAQ: ADXS) announced updated data from its Phase 1/2 study evaluating ADXS-503 in combination with Merck & Co Inc's Keytruda (pembrolizumab) in patients with metastatic non-small-cell lung cancer (NSCLC). Data will be presented at the American Society of...
-
Heat Biologics' Lead Candidate Shows Overall Survival Benefit In Lung Cancer Study
Thursday, May 20, 2021 - 10:06am | 296Read More...Heat Biologics Inc (NASDAQ: HTBX) has reported interim data from the Phase 1/2 trial evaluating its lead product, HS-110, in combination with Bristol-Myers Squibb Co's (NYSE: BMY) Opdivo (nivolumab) in advanced non-small-cell lung cancer (NSCLC) patients...
-
AstraZeneca's Tagrisso Scores Approval In China For Early Lung Cancer
Wednesday, April 14, 2021 - 9:16am | 191Read More...AstraZeneca Plc (NASDAQ: AZN) said that China’s health regulator had expanded the use of Tagrisso in patients with a type of lung cancer when diagnosed at an early stage. China’s National Medical Products Administration (NMPA) approved Tagrisso as adjuvant therapy...
-
Pulmatrix Stock Is Trading Lower After JNJ's Lung Cancer Initiative Terminates PUR1800 Licensing Pact
Monday, April 12, 2021 - 12:51pm | 288Read More...Pulmatrix Inc (NASDAQ: PULM) will regain full rights to its narrow spectrum kinase inhibitor (NSKI) portfolio, including PUR1800, following Johnsons & Johnson's (NYSE: JNJ) Enterprise Innovation's decision to terminate the license agreement. Pulmatrix...
-
FDA Ok's Roche's Companion Diagnostic For Pfizer's Lorbrena In Lung Cancer
Tuesday, March 9, 2021 - 8:22am | 213Read More...The FDA has approved Roche Holdings AG's (OTCMKT: RHHBY) Ventana ALK (D5F3) CDx Assay as a companion diagnostic to identify ALK-positive non-small cell lung cancer patients eligible for treatment with Pfizer Inc's (NYSE: PFE) Lorbrena (lorlatinib). The assay...
-
Sorrento Developed Socazolimab Enters Late-Stage Lung Cancer Study In China
Monday, March 8, 2021 - 8:05am | 211Read More...China's regulatory authorities have signed off on Lee's Pharmaceutical Holdings Limited's Phase 3 trial evaluating socazolimab in small-cell lung cancer. Lee Pharma has in-licensed socazolimab from Sorrento Therapeutics Inc (NASDAQ: SRNE) for the greater...
-
Biocept Inks Research Pact With Protean BioDiagnostics For Target Selector Kit Advantages In Lung Cancer
Tuesday, February 23, 2021 - 1:35pm | 211Read More...Biocept Inc (NASDAQ: BIOC) will collaborate with Protean BioDiagnostics Inc to research Biocept's Target Selector molecular assay's ability to determine EGFR status in non-small cell lung cancer (NSCLC) patients. The research will be conducted in an independent...
-
G1 Therapeutics' Trilaciclib Wins FDA Nod For Mitigating Chemo Effects In Lung Cancer Patients
Tuesday, February 16, 2021 - 5:37am | 180Read More...G1 Therapeutics Inc (NASDAQ: GTHX) shares gain premarket after FDA approves COSELA (trilaciclib) for injection to decrease the incidence of chemotherapy-induced myelosuppression (damage to bone marrow) in adult patients when administered before a platinum/etoposide-containing...
-
AstraZeneca Lung Cancer Drug Gets EU Approval
Tuesday, September 1, 2020 - 4:41am | 320Read More...AstraZeneca Plc’s (NYSE: AZN) developmental drug – Imfinizi, has been approved by the European Commission after the Phase 3 clinical trial yielded positive results. What Happened: Imfinizi is the first line of treatment for adults with extensive-stage small-cell lung cancer in choice...
-
Checkpoint Therapeutics CEO On Tapping Into A $25 Billion Cancer Treatment Market
Wednesday, May 20, 2020 - 8:33am | 1382Read More...The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Since its establishment in 2014 by founding company Fortress Biotech, Inc. (NASDAQ: FBIO), biopharmaceutical company Checkpoint...
-
Penny Stock Rips 260% Higher On Fast Track Designation For Experimental Lung Cancer Gene Therapy
Tuesday, January 21, 2020 - 12:40pm | 307Read More...Shares of thinly-traded gene therapy company Genprex Inc (NASDAQ: GNPX) are soaring on more than 50 times their average volume Tuesday. What Happened Genprex, which uses a non-viral, proprietary platform to deliver tumor suppressor genes to cancer cells, said the FDA has granted Fast Track...
